Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3858157 | 0.83 | ADORA1 (0.49) | KMT2ACYP1A2CASP1MEN1ADORA1 | |
| SCHEMBL31235463 | 0.79 | KMT2A (0.55) | KMT2ACYP1A2CASP1MEN1MAPT | |
| SCHEMBL11061657 | 0.76 | KMT2A (0.56) | KMT2ACYP1A2CASP1MAPTLMNA | |
| SCHEMBL7932287 | 0.75 | CYP1A2 (0.60) | KMT2ACYP1A2CASP1MAPTLMNA | |
| SCHEMBL16316421 | 0.75 | ADORA1 (0.56) | KMT2AMEN1ADORA1MAPTLMNA | |
| SCHEMBL2587336 | 0.75 | S1PR2 (0.62) | KMT2AMEN1ADORA1HTTMAPT | |
| SCHEMBL18037987 | 0.74 | KMT2A (0.63) | KMT2ACYP1A2CASP1MEN1HTT | |
| SCHEMBL14667356 | 0.73 | ADORA1 (0.46) | KMT2ACYP1A2MEN1ADORA1HTT | |
| SCHEMBL2033687 | 0.73 | HTT (0.51) | KMT2ACYP1A2MEN1ADORA1HTT | |
| SCHEMBL27815649 | 0.72 | KMT2A (0.48) | KMT2ACYP1A2CASP1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165334-A1 | Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors | AMGEN INC. (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165334-A1 | Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors | MTOR, PIKFYVE, RICTOR | KMT2A 1333/4885CYP1A2 2418/4885CASP1 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.